Literature DB >> 16336014

No room for kinkiness in a public healthcare system.

Jack Dowie1.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16336014     DOI： 10.2165/00019053-200523120-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

1.  Is there a kink in consumers' threshold value for cost-effectiveness in health care?

Authors:  Bernie J O'Brien; Kirsten Gertsen; Andrew R Willan; Lisa A Faulkner
Journal:  Health Econ       Date:  2002-03       Impact factor: 3.046

2.  Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant.

Authors:  Jack Dowie
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

Review 3.  Cost-effectiveness acceptability curves and a reluctance to lose.

Authors:  Johan L Severens; Daniëlle E M Brunenberg; Elisabeth A L Fenwick; Bernie O'Brien; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981
  3 in total
  6 in total

Review 1.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Loss aversion and cost effectiveness of healthcare programmes.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Loss aversion and cost effectiveness of healthcare programmes: whose aversion counts anyway?

Authors:  Johan L Severens; J L Hans Severens
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity.

Authors:  Adriënne H Rotteveel; Mattijs S Lambooij; Nicolaas P A Zuithoff; Job van Exel; Karel G M Moons; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

5.  Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Caveat emptor NICE: biased use of cost-effectiveness is inefficient and inequitable.

Authors:  Jack Dowie; Mette Kjer Kaltoft; Jesper Bo Nielsen; Glenn Salkeld
Journal:  F1000Res       Date:  2015-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.